Showing 1 - 3 results of 3 for search 'N. Angelosanto', query time: 0.02s Refine Results
  1. 1
    P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS

    P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS by U. Pakulska, N. Angelosanto, M. Mikula, H. Nogai, R. Dudziak, C. Abboud, M. Obacz, K. Goller, M. Cybulska, M. Mazan, M. Kozakowska, T. Rzymski

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P501: CLI120-001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE

    P501: CLI120-001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE by C. Abboud, Z. Jan Maciej, G. Borthakur, S. Solomon, B. Howard, T. Bradley, E. Mouhayar, N. Angelosanto, H. Nogai, A. Glasmacher, R. Dudziak, K. Brzozka, T. Rzymski, P. Littlewood, E.-L. Maranda

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.

    P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL. by G. Martinelli, A. Santoro, C. Gambacorti-Passerini, S. Vives Polo, S. R. Solomon, S. Mukherjee, E. Lech-Maranda, M. Yair Levy, A. Wierzbowska, M. Calbacho-Robles, G. Marconi, M. Benedetta Giannini, I. Cano, L. Torres Miñana, E. Acuña-Cruz, N. Angelosanto, A. Galleu, S. Baldini, S. Blotta, F. Ravandi, P. Montesinos

    Published 2022-06-01
    Get full text
    Article

Search Tools: